drug_type
RELEVANT_DRUG
intervention_type
Biological
drug_description
Also known as JSP191; a subcutaneous monoclonal antibody targeting c-KIT (CD117) that blocks stem cell factor binding to inhibit SCF/c-KIT signaling, depleting or functionally inhibiting c-KIT–dependent cells (notably tissue mast cells) to reduce mast-cell activation and mediator release.
nci_thesaurus_concept_id
C174050
nci_thesaurus_preferred_term
Briquilimab
nci_thesaurus_definition
A humanized monoclonal antibody directed against CD117 (tyrosine-protein kinase KIT; c-Kit; mast/stem cell growth factor receptor; SCFR), that can potentially be used to deplete hematopoietic stem cells (HSCs). Upon administration, briquilimab targets and binds to CD117. This prevents the binding of stem cell factor (SCF) to its receptor CD117 on HSCs. As CD117 binding to SCF is critical for survival and maintenance of blood forming stem cells, blocking this interaction causes the HSCs that are present in the bone marrow niches to be depleted. Briquilimab can potentially be used as a conditioning regimen to prepare patients for hematopoietic stem cell transplantation.
drug_mesh_term
Antibodies, Monoclonal
drug_category
INHIBITORY ANTIBODY
drug_class
Inhibitor
drug_delivery_route
Subcutaneous
drug_mechanism_of_action
Humanized monoclonal antibody against CD117 (c-KIT) that blocks stem cell factor (SCF) binding, inhibiting SCF/c-KIT signaling and depleting or functionally inhibiting c-KIT–dependent cells (notably mast cells and hematopoietic stem/progenitor cells), thereby reducing mast-cell activation and mediator release.
drug_name
Briquilimab
nct_id_drug_ref
NCT06353971